Erin K McCreary, Ravina Kullar, Matthew Geriak, Evan J Zasowski, Khulood Rizvi, Lucas T Schulz, Krista Ouellette, Logan Vasina, Fadi Haddad, Michael J Rybak, Marcus J Zervos, George Sakoulas, Warren E Rose
Background: Daptomycin and ceftaroline (DAP-CPT) have been used for persistent methicillin-resistant Staphylococcus aureus bacteremia (MRSAB), but have rarely been compared with other therapies. This study provides an exploratory analysis of patients placed on DAP-CPT vs standard of care (SOC) for MRSAB. Methods: This is a retrospective, matched cohort study MRSAB patients at 4 hospitals in the United States. Patients receiving DAP-CPT for ≥72 hours at any point in therapy were matched 2:1 when possible, 1:1 otherwise, to SOC, first by infection source, then age and renal function...
January 2020: Open Forum Infectious Diseases